FDA to expedite review of Takeda's ulcerative colitis drug

The FDA granted priority-review status to Takeda Pharmaceutical's application to market vedolizumab for the treatment of patients with moderately to severely active ulcerative colitis. The designation will shorten the drug review period from one year to eight months.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC